LAUSR

Asthma is a chronic inflammatory condition that affects 3.8 million Canadians and nearly 65 000 acute asthma exacerbations occur each year [1–4]. Left untreated, asthma can lead to increasing mortality and morbidity [2, 5, 6]. Economically, the projected 20-year total costs (2014–2033) of suboptimal asthma control in Canada are estimated to be $213 billion, of which the majority ($195 billion) were productivity losses (presenteeism and absenteeism) [7]. About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β2-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS